1 completed, 1 recruiting. 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Recruiting 1 |
Follow siponimod: new trials by email Literature Review of siponimod trials Research Report on siponimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod - Multiple Sclerosis, Relapsing-Remitting | Not applicable | Completed | Johns Hopkins University | 900 | 2018-05-02 | 2026-09-23 |
| Determinants of Warfarin Metabolism Warfarin, Phenytoin, Losartan & Hydrochlorothiazide - Healthy | Not applicable | Recruiting | Hadassah Medical Organization | 1000 | 2003-09-01 | 2026-04-21 |
Multiple Sclerosis, Relapsing-Remitting (1)
Hadassah Medical Organization (1) · Johns Hopkins University (1)
Israel (1) · United States (1)
Ellen M. Mowry, MD, MCR (1) · Scott D. Newsome, DO (1) · Yoseph Caraco, MD (1)